Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINE 2: IcoSema vs Semaglutide in Type 2 Diabetes
NCT05259033Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Peptides
- Countries
- 15
01
Overview
A Phase 3 trial of icosema in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Apr 2022; status: completed.
02
Drugs
icosema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05259033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259033.